Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CAMPATH-1H is a humanised mAb directed against lymphocytes. This mAb has been used to treat patients with rheumatoid arthritis. Clinical improvement with reduction in the Ritchie index and joint score has lasted for up to 8 months in some patients. A profound and prolonged lymphopaenia is induced by the mAb, with CD4+ numbers remaining suppressed for up to one year.


Conference paper

Publication Date



11 Suppl 8


S165 - S167


Animals, Antibodies, Monoclonal, Antigens, CD, Antigens, Neoplasm, Arthritis, Rheumatoid, CD52 Antigen, Glycoproteins, Humans, Leukocyte Count, Lymphocyte Depletion, Lymphocytes, Recombinant Fusion Proteins